Comparative immunogenicity of recombinant B domain-deleted porcine factor VIII and Hyate:C in hemophilia A mice presensitized to human factor VIII

Journal of Thrombosis and Haemostasis

Volumn 2, Issue 4, 2004, Pages 605-611

  Parker, E T ^a   Craddock, H N ^a   Barrow, R T ^a   Lollar, Pete ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

Acquired hemophilia; Factor VIII; Hemophilia A; Immunogenicity

Indexed keywords

BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 CONCENTRATE; RECOMBINANT B DOMAIN DELETED PORCINE BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG; B DOMAIN DELETED FACTOR VIII; B-DOMAIN-DELETED FACTOR VIII; BLOOD CLOTTING FACTOR 8; HETEROPHILE ANTIBODY; PEPTIDE FRAGMENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG RESPONSE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOPHILIA A; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RANDOMIZATION; ANIMAL; ANTIBODY PRODUCTION; BLOOD; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; IMMUNOLOGY; MOUSE MUTANT; SWINE;

ANIMALS; ANTIBODIES, HETEROPHILE; ANTIBODY FORMATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR VIII; HEMOPHILIA A; HUMANS; MICE; MICE, KNOCKOUT; PEPTIDE FRAGMENTS; SWINE;

EID: 5144220073     PISSN: 15387933     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2004.00685.x     Document Type: Article

References (21)

1. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS, and Kogenate Previously Untreated Patient Study Group. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and the development of inhibitors. N Engl J Med 1993; 328: 453-9.
2. Bray GL, Gomperts ED, Courtier S, Gruppo R, Gordon EM, Manco-Johnson M, Shapiro A, Scheibel E, White G, Lee M. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. Blood 1994; 83: 2428-35.
3. Kernoff PBA. Porcine factor VIII: preparation and use in treatment of inhibitor patients. In: Hoyer LW, ed. Factor VIII Inhihitors. New York: Alan R. Liss, 1984: 207-24.
4. Brettler DB, Forsberg AD, Levine PH, Aledort LM, Hilgartner MW, Kasper CK, Lusher JM, McMillan C, Roberts H. The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience. Arch Intern Med 1989; 149: 1381-5.
5. Gringeri A, Santagostino, E, Tradati F, Giangrande PL, Mannucci PM. Adverse effects of treatment with porcine factor VIII. Thromb Haemost 1991; 65: 245-7.
6. Hay CR, Lozier JN, Lee CA, Laffan M, Tradati F, Santagostino E, Ciavarella N, Schiavoni M, Fukui H, Yoshioka A, Teitel J, Mannucci PM, Kasper CK. Safety profile of porcine factor VIII and its use as hospital and home-therapy for patients with haemophilia-A and inhibitors: the results of an international survey. Thromb Haemost 1996; 75: 25-9.
7. Soucie JM, Erdman DD, Evatt BL, Anderson LJ, Torok TJ, El-Jamil M, Barnhart E, Tepper M, Burrill HN, Pickett AM, Mengeling WL. Investigation of porcine parvovirus among persons with hemophilia receiving Hyate:C porcine factor VIII concentrate. Transfusion 2000; 40: 708-11.
8. Hay CR. Porcine factor VIII: past, present and future. Haematologica 2000; 85: 21-4.
9. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 1995; 10: 119-21.
10. Qian J, Borovak M, Bi L, Kazazian HH Jr, Hoyer LW. Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A. Thromb Haemost 1999; 81: 240-4.
11. Christopoulos TK, Diamandis EP. Theory of immunoassays. In: Diamandis EP, Christopoulos TK, eds. Immunoassay. San Diego: Academic Press, 1996: 25-50.
12. Bevington PR. Least-squares fit to an arbitrary function. In: Data Reduction and Error Analysis for the Physical Sciences. New York: McGraw-Hill, 1969: 204-46.
13. Kasper CK, Aledort LM, Aronson D, Counts R, Edson JR, vanEys J, Fratatoni J, Green D, Hampton J, Hilgartner M, Levine P, Lazerson J, McMillan C, Penner J, Shapiro S, Schulman NR. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 869-72.
14. Qian J, Collins M, Sharpe AH, Hoyer LW. Prevention and treatment of factor VIII inhibitors in murine hemophilia A. Blood 2000; 95: 1324-9.
15. Qian J, Burkly LC, Smith EP, Ferrant JL, Hoyer LW, Scott DW, Haudenschild CC. Role of CD154 in the secondary immune response: the reduction of pre-existing splenic germinal centers and anti-factor VIII inhibitor titer. Eur J Immunol 2000; 30: 2548-54.
16. Reipert BM, Ahmad RU, Turecek PL, Schwarz HP. Characterization of antibodies induced by human factor VIII in a murine knockout model of hemophilia A. Thromb Haemost 2000; 84: 826-32.
17. Reipert BM, Sasgary M, Ahmad RU, Auer W, Turecek PL, Schwarz HP. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance. Thromb Haemost 2002; 86: 1345-52.
18. Sasgary M, Ahmad RU, Schwarz HP, Turecek PL, Reipert BM. Single cell analysis of factor VIII-specific T cells in hemophilic mice after treatment with human factor VIII. Thromb Haemost 2002; 87 266-72.
19. Durbin PW, Jeung N, Kullgren B, Clemons GK. Gross composition and plasma and extracellular water volumes of tissues of a reference mouse. Health Physics 1992; 63: 427-42.
20. Gilles JGG, Arnout J, Vermylen J, Saint-Remy JM. Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood 1993; 82: 2452-61.
21. Dazzi F, Tison T, Vianello F, Radossi P, Zerbinati P, Carraro P, Poletti A, Girolami A. High incidence of anti-FVIII antibodies against non-coagulant epitopes in haemophilia A patients: a possible role for the half- life of transfused FVIII. Br J Haematol 1996; 93: 688-93.